MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-26-2026
Country |
 France |
IPO year |
2014 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
140 M |
Market Cap[1] |
$ 2.88 B |
EBITDA (LTM) |
$ -83 M |
P/E (LTM) |
-17.12 |
P/S (LTM) |
660.4 |
EPS (LTM) |
-1.23 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Aquestive Therapeutics
AQST
|
$ 4.14 | 0.36 % | $ 443 M | Nasdaq Global Market |  USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
$ 8.41 | 4.73 % | $ 230 M | Nasdaq Global Market,SPB |  Israel |
 |
Ardelyx
ARDX
|
$ 6.06 | 1.94 % | $ 1.46 B | Nasdaq Global Market | USA |
 |
argenx SE
ARGX
|
$ 752.35 | 0.79 % | $ 25 B | Nasdaq Global Select Market |  Niderland |
 |
Arcutis Biotherapeutics
ARQT
|
$ 23.83 | 0.85 % | $ 3.03 B | Nasdaq Global Select Market,SPB | USA |
 |
Aytu BioScience
AYTU
|
$ 2.65 | -1.12 % | $ 16.6 M | Nasdaq Capital Market | USA |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market | France |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | France |
 |
BioCardia
BCDA
|
$ 1.2 | -0.04 % | $ 8 M | Nasdaq Global Select Market | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
$ 9.6 | 6.37 % | $ 1.98 B | Nasdaq Global Select Market | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$ 9.48 | -3.27 % | $ 613 M | NYSE | USA |
 |
BioVie
BIVI
|
$ 1.45 | 2.09 % | $ 2.14 M | Nasdaq Capital Market | USA |
 |
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | USA |
 |
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | USA |
 |
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market |  Canada |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
 |
BioLineRx Ltd.
BLRX
|
$ 2.32 | 4.98 % | $ 908 M | Nasdaq Capital Market | Israel |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
BioMarin Pharmaceutical
BMRN
|
$ 56.49 | 1.78 % | $ 10.8 B | Nasdaq Global Select Market,SPB | USA |
 |
BioNTech SE
BNTX
|
$ 92.3 | 1.23 % | $ 27.2 B | Nasdaq Global Select Market | Germany |
 |
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | USA |
 |
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | USA |
 |
Aileron Therapeutics
ALRN
|
- | 10.36 % | $ 9.8 M | Nasdaq Global Select Market | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
$ 3.04 | 1.54 % | $ 259 M | Nasdaq Capital Market | USA |
 |
BioXcel Therapeutics
BTAI
|
$ 1.16 | -2.12 % | $ 14.2 M | Nasdaq Global Select Market,SPB | USA |
 |
Burford Capital Limited
BUR
|
$ 4.54 | 9.54 % | $ 683 M | NYSE | Britain |
 |
Cabaletta Bio
CABA
|
$ 3.2 | 7.94 % | $ 322 M | Nasdaq Global Select Market | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 3.21 | 4.56 % | $ 6.98 B | NYSE American | Israel |
 |
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | USA |
 |
Catalyst Biosciences
CBIO
|
$ 19.97 | 2.94 % | $ 1.78 B | Nasdaq Capital Market | USA |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | Canada |
 |
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | USA |
 |
Codexis
CDXS
|
$ 1.97 | 7.97 % | $ 172 M | Nasdaq Global Select Market | USA |
 |
Cerus Corporation
CERS
|
$ 1.91 | 2.42 % | $ 364 M | Nasdaq Global Market | USA |
 |
Cullinan Management
CGEM
|
$ 15.4 | 6.72 % | $ 928 M | Nasdaq Global Select Market | USA |
 |
Coherus BioSciences
CHRS
|
$ 1.75 | 0.87 % | $ 205 M | Nasdaq Global Market | USA |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | Germany |
 |
AstraZeneca PLC
AZN
|
- | - | $ 96.9 B | Nasdaq Global Select Market | Britain |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.